The oncologist

Keyphrases

Publications

volume 29, number 8, 2024

Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The oncologist 29 (8) (2024)
Lorenzo Trippa, Sean Khozin
Unleashing the power of clinical trial data: a proposal for enhancing informed consent and data sharing. The oncologist 29 (8) (2024)
Bushra Shariff, Reagan M Barnett, Farshid Dayyani, Steven B Maron, Rory Mcgriskin, Samuel Klempner, Elifnur Yay Donderici, Nicole Zhang, Jude Masannat, Leylah M Drusbosky, Rutika Mehta
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers. The oncologist 29 (8) (2024)
Andreia Cristina de Melo, Evandro Lucena, Danielli Cristina Muniz de Oliveira, João P B Viola
Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment. The oncologist 29 (8) (2024)
Jin Li, Zhiqiang Wang, Haijun Zhong, Yifu He, Chen Zhang, Zuoxing Niu, Shujun Yang, Tao Zhang, Liangjun Zhu, Yongqian Shu, Yong Gao, Jianjun Peng, Yan Song, Jian Li, Ying Yuan, Haibo Zhang, Gengsheng Yu, Yunqi Hua, Jianjun Xiao, Jianfei Fu, Yulong Zheng, Hua Xue, Xian Luo, Ming Shi, Weiguo Su, Shu-Kui Qin
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice. The oncologist 29 (8) (2024)
Ying Li, Yuhui Pan, Zongwei Huang, Lishui Wu, Wenxi Wu, Siqi Xu, Zihan Chen, Xin Chen, Jun Lu, Sufang Qiu
Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma. The oncologist 29 (8) (2024)
Dean C Pavlick, Garrett M Frampton, Jeffrey R Ross
Understanding variants of unknown significance and classification of genomic alterations. The oncologist 29 (8) (2024)
Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. The oncologist 29 (8) (2024)
Andreia Cristina de Melo, Evandro Lucena, Danielli Cristina Muniz de Oliveira, João P B Viola
Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment. The oncologist 29 (8) (2024)
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. The oncologist 29 (8) (2024)
David J Stewart
Has the blood-brain barrier finally been busted? The oncologist 29 (8) (2024)
Meiting Chen, Riqing Huang, Rishang Chen, Fei Pan, Xiujiao Shen, Haifeng Li, Qixiang Rong, Xin An, Cong Xue, Yanxia Shi
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The oncologist 29 (8) (2024)
Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H Taylor, Kristen Neumann, May T Cho
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. The oncologist 29 (8) (2024)
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Archana M Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The oncologist 29 (8) (2024)
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. The oncologist 29 (8) (2024)
Arathi Mohan, Elit Quingalahua, Valerie Gunchick, Simi Paul, Chandan Kumar-Sinha, Oxana Crysler, Mark M Zalupski, Vaibhav Sahai
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. The oncologist 29 (8) (2024)
Mei Li M Kwong, James C Yang
Lifileucel: FDA-approved T-cell therapy for melanoma. The oncologist 29 (8) (2024)
Xiaolin Zhu, Emily Chan, Michelle L Turski, Carlos Espinosa Mendez, Sarah C Hsu, Vipul Kumar, Chase Shipp, Tanya Jindal, Kevin Chang, Courtney Onodera, W Patrick Devine, James P Grenert, Bradley A Stohr, Chien-Kuang Cornelia Ding, Matthew D Stachler, David A Quigley, Felix Y Feng, Carissa E Chu, Sima P Porten, Jonathan Chou, Terence W Friedlander, Vadim S Koshkin
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. The oncologist 29 (8) (2024)
Ke Zhou, Martine M Bellanger, Louise Crivelli, Sandy Laham, Charlotte Huet, Caroline Abadie
Factors Influencing Adherence to the Risk Management Program for Women With a Genetic Predisposition to Breast Cancer: Real-World Data from a French Multicenter Program. The oncologist 29 (8) (2024)
Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H Taylor, Kristen Neumann, May T Cho
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. The oncologist 29 (8) (2024)
Shuaishuai Xu, Linping Cao, Ruyin Chen, Chanqi Ye, Qiong Li, Qi Jiang, Feifei Yan, Mingyu Wan, Xiaochen Zhang, Jian Ruan
Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. The oncologist 29 (8) (2024)
Xue Shao, Qiulei Zhang, Ying Huo, Chang Lu
Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation. The oncologist 29 (8) (2024)
George S Mellgard, Zoey Atabek, Meredith LaRose, Fay Kastrinos, Susan E Bates
Variants of uncertain significance in precision oncology: nuance or nuisance? The oncologist 29 (8) (2024)
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08). The oncologist 29 (8) (2024)
Ying Li, Yuhui Pan, Zongwei Huang, Lishui Wu, Wenxi Wu, Siqi Xu, Zihan Chen, Xin Chen, Jun Lu, Sufang Qiu
Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma. The oncologist 29 (8) (2024)
Shuaishuai Xu, Linping Cao, Ruyin Chen, Chanqi Ye, Qiong Li, Qi Jiang, Feifei Yan, Mingyu Wan, Xiaochen Zhang, Jian Ruan
Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. The oncologist 29 (8) (2024)
Lei Wang, Jin-Kai Feng, Chong-De Lu, Jia-Yi Wu, Bin Zhou, Kang Wang, Xu-Biao Wei, Chao Liang, Hong-Kun Zhou, Jie Shi, Wei-Xing Guo, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The oncologist 29 (8) (2024)
George S Mellgard, Zoey Atabek, Meredith LaRose, Fay Kastrinos, Susan E Bates
Variants of uncertain significance in precision oncology: nuance or nuisance? The oncologist 29 (8) (2024)
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia, Anna Diana, Jessica Orefice, Liliana Ascione, Gloria Pellizzari, Nicola Fusco, Massimo Barberis, Bruno Daniele, Elena Guerini-Rocco, Curigliano Giuseppe
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The oncologist 29 (8) (2024)
Alex Fu, Raúl Rabadán
Understanding variants of unknown significance: the computational frontier. The oncologist 29 (8) (2024)
Jin Li, Zhiqiang Wang, Haijun Zhong, Yifu He, Chen Zhang, Zuoxing Niu, Shujun Yang, Tao Zhang, Liangjun Zhu, Yongqian Shu, Yong Gao, Jianjun Peng, Yan Song, Jian Li, Ying Yuan, Haibo Zhang, Gengsheng Yu, Yunqi Hua, Jianjun Xiao, Jianfei Fu, Yulong Zheng, Hua Xue, Xian Luo, Ming Shi, Weiguo Su, Shu-Kui Qin
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice. The oncologist 29 (8) (2024)
Xue Shao, Qiulei Zhang, Ying Huo, Chang Lu
Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation. The oncologist 29 (8) (2024)
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08). The oncologist 29 (8) (2024)
Lorenzo Trippa, Sean Khozin
Unleashing the power of clinical trial data: a proposal for enhancing informed consent and data sharing. The oncologist 29 (8) (2024)
Hassan Hatoum, Alexander Rosemurgy, J Augusto Bastidas, Emmanuel Zervos, Peter Muscarella, Barish H Edil, Jacob Cynamon, D Thor Johnson, Christopher Thomas, Bradley M Swinson, Aaron Nordgren, Paul Vitulli, Charles Nutting, Matthew Gipson, Alex Tsobanoudis, Ramtin Agah
Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. The oncologist 29 (8) (2024)
Philip C Mack, Rachel B Keller-Evans, Gerald Li, Katherine T Lofgren, Alexa B Schrock, Sally E Trabucco, Justin M Allen, Khaled Tolba, Geoffrey R Oxnard, Richard S P Huang
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC. The oncologist 29 (8) (2024)
Riad Salem, Etienne Garin, Eveline Boucher, Kirk Fowers, Marnix Lam, Siddharth Padia, William Harris
Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study. The oncologist 29 (8) (2024)
Lei Wang, Jin-Kai Feng, Chong-De Lu, Jia-Yi Wu, Bin Zhou, Kang Wang, Xu-Biao Wei, Chao Liang, Hong-Kun Zhou, Jie Shi, Wei-Xing Guo, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The oncologist 29 (8) (2024)
Casey Timmerman, Isabel Naraine, Tian Zhang
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. The oncologist 29 (8) (2024)
Endong Chen, Chen Chen, Yingying Chen, Jie You, Chun Jin, Zhenxuan Huang, Jiayi Zhang, Qingxuan Wang, Yefeng Cai, Xiaoqu Hu, Quan Li
Insights into the performance of PREDICT tool in a large Mainland Chinese breast cancer cohort: a comparative analysis of versions 3.0 and 2.2. The oncologist 29 (8) (2024)
Marie V Nelson, Ae Rang Kim, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent D Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez, Alok Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, D Williams Parsons
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. The oncologist 29 (8) (2024)
Marie V Nelson, Ae Rang Kim, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent D Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez, Alok Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, D Williams Parsons
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. The oncologist 29 (8) (2024)
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia, Anna Diana, Jessica Orefice, Liliana Ascione, Gloria Pellizzari, Nicola Fusco, Massimo Barberis, Bruno Daniele, Elena Guerini-Rocco, Curigliano Giuseppe
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The oncologist 29 (8) (2024)
David J Stewart
Has the blood-brain barrier finally been busted? The oncologist 29 (8) (2024)
Xiaolin Zhu, Emily Chan, Michelle L Turski, Carlos Espinosa Mendez, Sarah C Hsu, Vipul Kumar, Chase Shipp, Tanya Jindal, Kevin Chang, Courtney Onodera, W Patrick Devine, James P Grenert, Bradley A Stohr, Chien-Kuang Cornelia Ding, Matthew D Stachler, David A Quigley, Felix Y Feng, Carissa E Chu, Sima P Porten, Jonathan Chou, Terence W Friedlander, Vadim S Koshkin
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. The oncologist 29 (8) (2024)
Bushra Shariff, Reagan M Barnett, Farshid Dayyani, Steven B Maron, Rory Mcgriskin, Samuel Klempner, Elifnur Yay Donderici, Nicole Zhang, Jude Masannat, Leylah M Drusbosky, Rutika Mehta
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers. The oncologist 29 (8) (2024)
Alex Fu, Raúl Rabadán
Understanding variants of unknown significance: the computational frontier. The oncologist 29 (8) (2024)
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Archana M Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The oncologist 29 (8) (2024)
Ke Zhou, Martine M Bellanger, Louise Crivelli, Sandy Laham, Charlotte Huet, Caroline Abadie
Factors Influencing Adherence to the Risk Management Program for Women With a Genetic Predisposition to Breast Cancer: Real-World Data from a French Multicenter Program. The oncologist 29 (8) (2024)
Philip C Mack, Rachel B Keller-Evans, Gerald Li, Katherine T Lofgren, Alexa B Schrock, Sally E Trabucco, Justin M Allen, Khaled Tolba, Geoffrey R Oxnard, Richard S P Huang
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC. The oncologist 29 (8) (2024)